Unknown

Dataset Information

0

Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.


ABSTRACT: COVID-19 pandemic has severely impacted the public health and social economy worldwide. A safe, effective, and affordable vaccine against SARS-CoV-2 infections/diseases is urgently needed. We have been developing a recombinant vaccine based on a prefusion-stabilized spike trimer of SARS-CoV-2 and formulated with aluminium hydroxide and CpG 7909. The spike protein was expressed in Chinese hamster ovary (CHO) cells, purified, and prepared as a stable formulation with the dual adjuvant. Immunogenicity studies showed that candidate vaccines elicited robust neutralizing antibody responses and substantial CD4+ T cell responses in both mice and non-human primates. And vaccine-induced neutralizing antibodies persisted at high level for at least 6 months. Challenge studies demonstrated that candidate vaccine reduced the viral loads and inflammation in the lungs of SARS-CoV-2 infected golden Syrian hamsters significantly. In addition, the vaccine-induced antibodies showed cross-neutralization activity against B.1.1.7 and B.1.351 variants. These data suggest candidate vaccine is efficacious in preventing SARS-CoV-2 infections and associated pneumonia, thereby justifying ongoing phase I/II clinical studies in China (NCT04982068 and NCT04990544).

SUBMITTER: Liu H 

PROVIDER: S-EPMC8556577 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4494345 | biostudies-literature
| S-EPMC7676267 | biostudies-literature
| S-EPMC8233066 | biostudies-literature
| S-EPMC8062487 | biostudies-literature
| S-EPMC6491494 | biostudies-literature
| S-EPMC3529788 | biostudies-literature
| S-EPMC8789674 | biostudies-literature
| S-EPMC8000430 | biostudies-literature
| S-EPMC7097490 | biostudies-literature
| S-EPMC7753443 | biostudies-literature